Thromboembolic Risk of 4 Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department by Maguire, Michelle et al.
UC Irvine
Western Journal of Emergency Medicine: Integrating Emergency 
Care with Population Health
Title
Thromboembolic Risk of 4 Factor Prothrombin Complex Concentrate versus Fresh Frozen 
Plasma for Urgent Warfarin Reversal in the Emergency Department
Permalink
https://escholarship.org/uc/item/2b39723b
Journal
Western Journal of Emergency Medicine: Integrating Emergency Care with Population 
Health, 20(4)
ISSN
1936-900X
Authors
Maguire, Michelle
Fuh, Lanting
Goldstein, Joshua N.
et al.
Publication Date
2019
DOI
10.5811/westjem.2019.4.41649
License
CC BY 4.0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Volume 20, no. 4: July 2019 619 Western Journal of Emergency Medicine
Original research
 
Thromboembolic Risk of 4-Factor Prothrombin Complex 
Concentrate versus Fresh Frozen Plasma for Urgent Warfarin 
Reversal in the Emergency Department
 
Michelle Maguire, PharmD*
Lanting Fuh, PharmD*
Joshua N. Goldstein, MD, PhD†¶
Ariela L. Marshall, MD#**
Michael Levine, MD††
Melissa L. Howell, BS‡‡
Blair A. Parry, BA†‡
Rachel Rosovsky, MD§||
Bryan D. Hayes, PharmD*¶
Section Editor: Gabriel Wardi, MD     
Submission history: Submitted November 14, 2018; Revisions received April 25, 2019; Accepted April 26, 2019  
Electronically published June 11, 2019         
Full text available through open access at http://escholarship.org/uc/uciem_westjem   
DOI: 10.5811/westjem.2019.4.41649
Introduction: Warfarin is a potent anticoagulant used for the prevention and treatment of venous and arterial 
thrombosis. Occasionally, patients require emergent warfarin reversal due to active bleeding, supratherapeutic 
international normalized ratio, or emergent diagnostic or therapeutic interventions. Various agents can be 
used for emergent warfarin reversal, including fresh frozen plasma (FFP) and 4-factor prothrombin complex 
concentrate (4F-PCC). Both FFP and 4F-PCC are generally considered safe; however, both agents contain 
coagulation factors and have the potential to provoke a thromboembolic event. Although clinical trials have 
compared the efficacy and safety of FFP and 4F-PCC, data are limited comparing the risk of thromboembolism 
between the two agents.  
Methods: A retrospective chart review was performed at a single, urban, academic medical center comparing 
the incidence of thromboembolism with FFP or 4F-PCC for warfarin reversal during a three-year period in the 
emergency department (ED) at Massachusetts General Hospital. Patients were included in the study if they 
were at least 18 years of age and were on warfarin per electronic health records. Patients were excluded if 
they had received both FFP and 4F-PCC during the same visit. The primary outcome was the frequency of 
thromboembolism within 30 days of 4F-PCC or FFP. Secondary outcomes included time to thromboembolic 
event and in-hospital mortality.
 
Results: Three hundred and thirty-six patients met the inclusion criteria. Thromboembolic events within 30 days 
of therapy occurred in seven patients (2.7%) in the FFP group and 14 patients (17.7%) in the 4F-PCC group 
(p=<0.001). Death occurred in 39 patients (15.2%) who received FFP and 18 patients (22.8%) who received 
4F-PCC (p=0.115). Since the 4F-PCC group was treated disproportionately for central nervous system (CNS) 
bleeding, a subgroup analysis was performed including patients requiring reversal due to CNS bleeds that 
received vitamin K. The primary outcome remained statistically significant, occurring in four patients (4.1%) in 
the FFP group and nine patients (14.1%) in the 4F-PCC group (p=0.02). 
Conclusion: Our study found a significantly higher risk of thromboembolic events in patients receiving 4F-PCC 
compared to FFP for urgent warfarin reversal. This difference remained statistically significant when controlled for 
CNS bleeds and administration of vitamin K. [West J Emerg Med. 2019;20(4)619-625.]
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Population Health Research Capsule
What do we already know about this issue?
Despite clinical trials of fresh frozen plasma 
(FFP) vs. 4-factor prothrombin complex 
concentrate (4F-PCC), few data compare 
thromboembolism risk for warfarin reversal.
What was the research question?
What is the incidence of thromboembolism 
using FFP compared to 4F-PCC for urgent 
warfarin reversal?
What was the major finding of the study?
There was a higher risk of thromboembolic 
events in patients receiving 4F-PCC compared 
to FFP for urgent warfarin reversal. 
How does this improve population health?
While 4F-PCC is the preferred agent for 
warfarin reversal, providers must weigh the 
risks and benefits when using it in patients 
already at high risk of thromboembolism.
INTRODUCTION
Warfarin is a potent anticoagulant used for the 
prevention and treatment of venous and arterial thrombosis. 
As a vitamin K antagonist, warfarin prevents the post-
translational carboxylation of coagulation factors II, 
VII, IX, and X, along with protein C and S, by 30-50%.1 
Warfarin is one of the top medications implicated in 
emergency department (ED) visits due to bleeding events. 
Annually, bleeding complications associated with over-
anticoagulation with warfarin occur in 15-20% of patients, 
with fatal bleeds accounting for 1-3%.2
Occasionally, patients require emergent warfarin 
reversal due to life-threatening bleeds or the need for 
emergency diagnostic or therapeutic intervention. The risk 
of bleeding is directly related to the degree of international 
normalized ratio (INR) elevation.3 It is important to note, 
however, that half of all major bleeding episodes associated 
with warfarin occur when the INR is less than 4.0.4 The 
degree and rapidity of reversal are dependent upon not 
only the absolute value of the INR, but also the clinical 
indication for reversal. Prior to the approval of 4-factor-
prothrombin complex concentrate (4F-PCC) in 2013, fresh 
frozen plasma (FFP) was the preferred therapy for reversing 
warfarin in the United States. However, 4F-PCC reduces 
the INR more quickly and is now preferred as a first-line 
agent for warfarin reversal in intracranial hemorrhage, 
the most disabling form of major bleeding.5,6,7,8,9 Both FFP 
and 4F-PCC are generally considered safe; however, both 
agents contain coagulation factors and have the potential to 
provoke a thromboembolic event. Although clinical trials 
have compared the efficacy and safety of FFP and 4F-PCC, 
there is sparse data comparing the risk of thromboembolism 
between the two agents outside the clinical trial setting, 
using “real world” data. 6,7,10,11,12,13,14
The primary objective of this study was to assess the 
incidence of thromboembolic events in patients who received 
either 4F-PCC or FFP for emergent warfarin reversal. 
METHODS
We performed a retrospective chart review at a single, 
urban, academic medical center. Consecutive patients 
receiving 4F-PCC in the ED between April 20, 2016 – 
October 28, 2017, or FFP in the ED between January 1, 
2010 – January 30, 2011, were identified from the electronic 
health record (EHR). During the FFP period, 4F-PCC was 
not available for use at our institution, and FFP was used 
for all emergent warfarin reversal. In April 2013, 4F-PCC 
became available for warfarin reversal, although its use was 
restricted to patients with central nervous system (CNS) and 
intrapulmonary bleeds on warfarin. Any other indications 
required hematology approval. A report from the hospital’s 
EHR identified patients who received an order for FFP or 
4F-PCC while in the ED. 
Patients were included in the current study if they 
were at least 18 years of age and were on warfarin as 
per EHR, including outpatient medication lists, previous 
prescriptions, and prescriber notes. We excluded patients if 
they had received both FFP and 4F-PCC during the same 
visit. Collected data included initial INR on presentation 
to the ED, indication for warfarin, indication for warfarin 
reversal, administration and dose of FFP or 4F-PCC, 
administration of vitamin K, thromboembolic events, 
and mortality. Age, gender, and race were also collected 
for demographic purposes. Thromboembolic events 
were identified by reviewing provider notes, discharge 
summaries, follow-up notes, imaging, and medication 
administration records. 
We used the search function of the EHR to ensure 
that no thromboembolic events occurring at our hospital 
were overlooked. This search function identifies the 
searched term in the EHR, as well as any other medically 
related terms. For example, when searching for the term 
“clot,” similar search terms such as thromboembolism and 
thrombus are also identified. Patients in the FFP group were 
originally collected for a separate analysis of pulmonary 
complication rates after FFP administration and time to 
INR reversal.15 
Abstractors were trained in clinical research and quality 
assurance. There was an initial review of study variables, 
standard operating procedures for data abstraction, 
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and the data abstraction form (which was electronic, 
using REDCap). Each abstractor then reviewed a set of 
practice records, with variables verified for accuracy and 
discrepancies adjudicated. After training, regular meetings 
occurred to review data collection and address questions 
and discrepancies.
The primary outcome was the frequency of 
thromboembolism within 30 days of 4F-PCC or FFP 
administration. Secondary outcomes included time to 
thromboembolic event and in-hospital mortality. 
Statistical Analysis
This study was approved by the institutional review board. 
We collected and analyzed data using RedCap and Excel. We 
used chi-square tests to compare the rate of thromboembolic 
events and mortality between patients who received 4F-PCC 
and FFP. The method by Cohen was used to determine power 
since there were no previous studies on which to base our 
power analysis.16 In order to detect a medium effect size 
difference (d = 0.5 where d = (meana-meanb)/α) and α = 
0.05), it was estimated that 64 patients would be required for 
each group. We also calculated Cohen’s kappa to assess for 
inter-rater reliability. This number was based on 10% of our 
data chosen at random to be reabstracted by an independent 
reviewer for our primary endpoint. 
RESULTS
Table 1 shows patients’ baseline characteristics. The 
most common reason for patients to receive 4F-PCC was 
CNS bleed (82.3%), while the indications for FFP were 
more varied, including CNS bleed (38.1%), urgent surgery 
(25.7%), and gastrointestinal bleed (19.8%). The median 
amount of FFP administered was 3 units (interquartile 
range [IQR] 1-3) with the average dose being 9.4 milliliters 
per kilogram (mL/kg). The mean dose of 4F-PCC 
administered was 2168 units (standard deviation [SD] 723 
units). All patients included in the 4F-PCC group received 
a dose within 10% of their calculated dose based on their 
initial INR and weight, consistent with U.S. Food and Drug 
Administration (FDA)-approved dosing. Inclusion and 
exclusion criteria are described in Figure 1. 
The primary outcome, thromboembolic events within 30 
days, occurred in seven patients (2.7%) in the FFP group and 
14 patients (17.7%) in the 4F-PCC group (p=<0.001). We 
calculated a Cohen’s kappa score of 0.84 based on 10% of the 
data reabstracted by an independent reviewer. The mean time to 
thromboembolic event was 4.1 days (SD 5.4) in the FFP group 
and 8.9 days (SD 8.7) in the 4F-PCC group (p=0.20). We also 
evaluated thromboembolic events based on type and indications 
for warfarin use, as seen in Tables 2 and 3. Two patients in 
the FFP group and four patients in the 4F-PCC group had 
superficial clots, all of which were cephalic vein thromboses. 
When these less dangerous and non-life-threatening clots were 
removed from the analysis, the difference in thromboembolic 
events remained statistically significant (p=<0.001) between the 
two groups. 
Vitamin K was administered in 209 of 257 (81.3%) patients 
in the FFP group and 78 of 79 (98.7%) patients in the 4F-PCC 
group (p=0.0002). Death occurred in 39 patients (15.2%) who 
received FFP and 18 patients (22.8%) who received 4F-PCC 
(p=0.115). Cause of death in the FFP group was attributed to 
a bleeding event in 20 patients and thromboembolic event in 
two patients, while 17 patients had other, non-related or unclear 
causes of death. In the 4F-PCC group, death was attributed to 
a bleeding event in 10 patients and thromboembolic event in 
two patients, while six patients had other, non-related or unclear 
causes of death. All bleeding events resulting in death were 
attributed to the presenting event. 
As the 4F-PCC group was treated disproportionately 
for CNS bleeding (due to the hospital guideline restricting 
4F-PCC use to high-risk conditions such as this), we 
performed a subgroup analysis including only patients 
requiring warfarin reversal due to CNS bleeds and those that 
received vitamin K in the ED. There were 98 patients included 
in the FFP group and 65 patients included in the 4F-PCC 
group. The median amount of FFP administered was 4 units 
(IQR 1-3), while the mean dose of 4F-PCC administered 
was 2148 units (SD 698 units). The primary outcome, 
thromboembolic events within 30 days, remained statistically 
significant occurring in four patients (4.1%) in the FFP group 
and nine patients (14.1%) in the 4F-PCC group (p=0.02). 
Death occurred in 30 patients (30.6%) who received FFP and 
17 patients (26.2%) who received 4F-PCC (p=0.54). 
DISCUSSION
According to the American College of Cardiology 
(ACC) and the Neurocritical Care Society guidelines on 
anticoagulation reversal, 4F-PCC is currently recommended 
as the preferred method for emergency warfarin reversal.8,9 
Although patients receiving warfarin have pre-existing 
thromboembolic risk factors that may be unmasked with 
reversal, it is not clear whether different warfarin reversal 
options carry different thromboembolic risks. Phase 2 and 
3 clinical trials evaluating thromboembolic events between 
FFP and 4F-PCC for vitamin K antagonist reversal found 
no difference between these options.5,6,7,17 However, our 
study of real-world data suggests the thromboembolic 
risk of 4F-PCC may be higher than FFP. Importantly, the 
thromboembolic events in the 4F-PCC group, on average, 
occurred much later in the clinical course and therefore 
may be less related to the initial reversal administered. 
Although this difference was not statistically significant, it 
could have clinically significant implications. 
Several factors may have contributed to the difference 
in thromboembolic risk in our study, the first of which 
is the differences in baseline characteristics. Patients 
who received 4F-PCC had a significantly higher rate of 
atrial fibrillation requiring warfarin therapy, while more 
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4F-PCC (n=79) FFP (n=257) p-value 
Sex
Male 59.5% 59.1% 0.96
Female 40.5% 40.9% 0.96
Age (years) 75.2 73.0 0.09
Race
Hispanic/Latino 2 (2.5%) 4 (1.6%) 0.57
Not Hispanic/Latino 76 (96.2%) 252 (98.0%) 0.35
Unavailable 1 (1.3%) 1 (0.4%) 0.38
Weight (kg) 78.3 79.8 0.26
Baseline INR 3.65 3.86 0.37
Indication for Warfarin*
Atrial fibrillation 60 (75.9%) 162 (63.0%) 0.03
Mitral valve replacement 4 (5.1%) 7 (2.7%) 0.31
Aortic valve replacement 6 (7.6%) 13 (5.1%) 0.39
Deep vein thrombosis 7 (8.8%) 41 (15.9%) 0.12
Pulmonary embolism 4 (5.1%) 36 (14.0%) 0.03
Hypercoagulable state 5 (6.3%) 11 (4.3%) 0.45
Other 3 (3.8%) 57 (22.1%) <0.001
Indication for Warfarin reversal*
CNS bleed 65 (82.3%) 98 (38.1%) <0.001
GI bleed 5 (6.3%) 51 (19.8%) 0.005
Musculoskeletal bleed 3 (3.8%) 2 (0.8%) 0.05
Intra-abdominal bleed 0 (0%) 10 (3.9%) 0.13
Hematuria 0 (0%) 4 (1.6%) 0.58
Hemoptysis 0 (0%) 3 (1.2%) 1.0
Epistaxis 0 (0%) 2 (0.8%) 1.0
Hematoma 4 (5.1%) 4 (1.6%) 0.07
Hemothorax 0 (0%) 1 (0.4%) 1.0
Other bleeding** 0 (0%) 7 (2.7%) 0.21
Surgery 4 (5.1%) 66 (25.7%) <0.001
Other indications for reversal 0 (0%) 7 (2.7%) 0.21
Average dose 28 IU/kg 9.4 mL/kg
Concomitant vitamin K 78 (98.7%) 209 (81.3%) <0.001
Table 1. Baseline characteristics.
*Numbers do not add up to 100% as some patients had more than one indication for warfarin or warfarin reversal. 
**Other bleeding includes vaginal bleeding, catheter site bleeding, arteriovenous fistula, hemorrhagic ovarian cyst, hemorrhagic goiter, 
bleeding associated with multi-trauma, and hemathrosis. 
FFP, fresh frozen plasma; 4F-PCC, 4-factor prothrombin complex concentrate; kg, kilogram; INR, international normalized ratio; CNS, 
central nervous system; GI, gastrointestinal; mL/kg, milliliters per kilogram; IU/kg, international unit per kilogram.
FFP patients were under treatment for thromboembolic 
disorders such as pulmonary emboli. Patients in the FFP 
group had an overall higher risk of venous thromboemboli, 
potentially putting them at higher risk of thromboembolic 
events with warfarin reversal. Our results demonstrated the 
opposite, suggesting that the patients in the 4F-PCC group 
may have an increased risk of thromboembolic events 
despite their indication for warfarin.
The dose of FFP administered and differences in 
vitamin K administration may also have contributed. 
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When using FFP for the emergency reversal of warfarin, 
10-15mL/kg is recommended.9 Most adults will need an 
average dose of 3-6 units to replace enough coagulation 
factors to reverse warfarin. In our study, the median 
amount of FFP given was 3 units, with the group having 
a mean weight of 79.8 kg. On average, patients in our 
study received a subtherapeutic dose of FFP at 9.4 mL/
kg, while all patients in the 4F-PCC group received the 
recommended dose based on their weight and INR. For 
comparison, the FFP arms of clinical trials include doses 
that are substantially higher than those used in our center 
during the study period;6,7,17 therefore, our FFP patients may 
have been exposed to lower thromboembolic risk. Although the 
average FFP dose administered in our study was subtherapeutic 
according to the guidelines, it was within 10% of the lower limit 
of the recommended dose of 10 mL/kg, which suggests that the 
lower end of the dosing range may be safer. 
The difference in Vitamin K administration might also have 
contributed to the difference in thromboembolic events. The 
FFP group received vitamin K significantly less often than 
the 4F-PCC group (81% vs.99%, respectively; p = <0.001), a 
difference that was not seen in most other studies.5,6,7
Another difference identified between the two groups 
was the number of CNS bleeds. Our hospital guideline allows 
4F-PCC to be ordered without specialist approval for patients 
with CNS bleeds; however, most other uses require hematology 
approval. To control for this, we performed a subgroup analysis 
examining only those with CNS bleeds who received vitamin 
K. The thromboembolic event rate remained higher in the 
4F-PCC group. However, there was no difference in mortality. 
It remains possible that providers selected more severely injured 
patients for 4F-PCC.18 
Several studies examined the difference between 
thromboembolic events as a secondary outcome, but only a few 
have looked at this occurrence as a primary outcome.5,6,7,17 A post 
Excluded (n=78)
Did not receive FFP (n=6)
Not actively on warfarin (n=72)
Excluded (n=35)
Did not receive 4F-PCC (n=3)
Received both FFP and 
4F-PCC (n=28)
Not actively on warfarin (n=4)
Assessed for eligibility (n=449)
FFP group 
(n=335)
4F-PCC group
(n=114)
Patients included in the 
FFP analysis (n=257)
Patients included in the 
4F-PCC analysis (n=79)
Figure 1. Study inclusion and exclusion. 
FFP, fresh frozen plasma; 4F-PCC, 4-factor prothrombin complex concentrate.
4F-PCC (14) FFP (7) p-value 
Myocardial infarction 0 (0%) 1 (14.3%) 0.33
Cerebral vascular 
accident
2 (14.3%) 0 (0%) 0.53
Pulmonary embolism 2 (14.3%) 1 (14.3%) 1
Deep venous 
thrombosis
4 (28.6%) 3 (42.9%) 0.64
Superficial thrombosis* 4 (28.6%) 2 (28.6%) 1
Other** thromboembolic 
event
2 (14.3%) 0 (0%) 0.53
Table 2. Thromboembolic events within 30 days of warfarin reversal.
*Superficial thrombosis includes cephalic vein thrombus.
**Other events include left ventricular thrombus and right atrial 
thrombus. 
FFP, fresh frozen plasma; 4F-PCC, 4-factor prothrombin complex 
concentrate.
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hoc exploratory analysis of two randomized controlled trials 
found that most thromboembolic events in the 4F-PCC group 
occurred >7 days after reversal, clustering around the two-week 
mark while thromboembolic events in the FFP group occurred 
within seven days of reversal, with nearly 50% occurring within 
the same day. This difference may be due to the increased 
amount of vitamin K and non-vitamin K dependent coagulation 
factors being loaded over a short period but also raises the 
question of whether the thromboembolic events were caused by 
the administration of 4F-PCC or a consequence of prolonged 
hospitalizations and delayed anticoagulation initiation after a 
major bleeding event. 
The ACC published an expert consensus on the management 
of bleeding in patients on oral anticoagulants, in which they 
recommend the use of either variable dosing of 4F-PCC 
based on INR and weight or fixed dose.9 There are few data to 
suggest that the rate of thromboembolic events with 4F-PCC 
is dose dependent. However, giving a fixed dose of 1000-
1500 international units may theoretically reduce the risk of 
thromboembolic events. Since our study used the variable FDA 
dosing of 4F-PCC based on INR and weight, further studies are 
needed to determine if the risk of thromboembolic events would 
remain significant between FFP and 4F-PCC when using fixed 
dose 4F-PCC.  
LIMITATIONS
Limitations of this study include its retrospective, single-
center design, which only included patients seen and followed up 
at our hospital. Although we were able to identify all patients that 
followed up at hospitals within our healthcare system, patients 
may have been missed if they had thromboembolic events or 
Thromboembolic event
Warfarin Indication*
4F-PCC FFP
Cerebral vascular accident (n=1 in 4F-PCC) Atrial fibrillation (n=1)
Cerebral vascular accident (n=1)
None
Myocardial infarction (n=1) None Atrial fibrillation (n=1)
Pulmonary embolism (n=2 in 4F-PCC and 1 in FFP) Atrial fibrillation (n=2)
Deep venous thrombosis (n=1)
Deep venous thrombosis (n=1)
Hypercoagulable state (n=1)
Deep venous thrombosis (n=4 in 4F-PCC and 4 in FFP) Atrial fibrillation (n=4)
Deep venous thrombosis (n=1)
Factor V Leiden (n=1)
Atrial Fibrillation (n=3)
Deep venous thrombosis (n=1)
Hypercoagulable state (n=2)
Superficial thrombosis (n= 4 in 4F-PCC and 2 in FFP) Mechanical valve (n=2)
Atrial fibrillation (n=3)
Pulmonary embolism (n=1)
Deep venous thrombosis (n=1) 
Hypercoagulable state (n=1)
Other thromboembolic event (n=2 in 4F-PCC) Atrial fibrillation (n=1)
Mechanical valve (n=1)
Deep venous thrombosis (n=1)
None
Table 3. Warfarin indications for patients with thromboembolic events after reversal with 4-factor prothrombin complex concentrate (4F-PCC) 
or fresh frozen plasma (FFP).
*Warfarin indications were not mutually exclusive.
FFP, fresh frozen plasma; 4F-PCC, 4-factor prothrombin complex concentrate.
died at hospitals outside of our system. Another limitation is the 
difference in time periods in which the data were collected and 
the difference in baseline characteristics between the two groups. 
Although 4F-PCC was FDA approved in 2013, its distribution 
was managed by the blood bank at our institution until 2016, 
when it was transferred to the pharmacy department.18 Due to 
this timing, we were unable to obtain any data for 4F-PCC use 
before this time. To ensure inter-rater reliability an independent 
abstractor conducted quality assurance using the Cohen’s 
kappa score by reabstracting 10% of the data. Despite the 
difference in abstractors and time periods, a kappa score of 0.84 
suggested almost perfect agreement between the abstractors. 
In addition, clinical care of patients requiring warfarin reversal 
may have changed during the study period, and data capture 
for thromboembolic events may have improved, artificially 
increasing the frequency of thromboembolism over time. Lastly, 
we are unable to comment on the long-term morbidity and 
mortality between the two groups as this study only analyzed data 
up to 30 days after patients received 4F-PCC and FFP.
CONCLUSION
Our study found a higher risk of thromboembolic events in 
patients receiving FDA-approved doses of 4F-PCC compared 
to FFP for urgent warfarin reversal. This difference remained 
when controlled for CNS bleeds and administration of vitamin 
K. Thromboembolic events, on average, developed several 
days later in the 4F-PCC group compared to the FFP group. 
Although 4F-PCC is the preferred agent for emergent warfarin 
reversal, it is important for providers to weigh the risks and 
benefits when using this agent in patients already at high risk of 
thromboembolic events. 
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